CLINICAL_TRIALS
trial_result
· 2017-08-10
Clinical Trial Update: NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia [Phase 2]
Summary
The document reports the completion and posted results of a Phase 2 dose-titration trial of NBI-98854 for tardive dyskinesia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Neurocrine Biosciences | Conditions: Tardive Dyskinesia | Phase 2 | Status: COMPLETED | Results posted: 2017-08-10